Kristin Taylor

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Daniel J. Drucker, John B. Buse, Kristin Taylor et al. · The Lancet · 2008 · 1.1K citations

Medicine, Endocrinology, Pharmacotherapy +12

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Orville Kolterman, John B. Buse, Mark Fineman et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 554 citations · Full text

Medicine, Endocrinology, Pharmacology +17

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 446 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Dennis Kim, Leigh MacConell, Dongliang Zhuang et al. · Diabetes Care · 2007 · 446 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Michaëla Diamant, Luc Van Gaal, Stephen Stranks et al. · The Lancet · 2010 · 436 citations

Medicine, Endocrinology, Pharmacology +14